Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | BCL9 | O00512 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4947771 | 0.92 | PRMT5 (0.43) | PRMT5HTR6ALOX5APFEN1TLR9 | |
| SCHEMBL4946491 | 0.91 | SCN9A (0.47) | PRMT5PARP1HTR6ALOX5APFEN1 | |
| SCHEMBL4947749 | 0.91 | HPGD (0.41) | PRMT5TP53HTR6ALOX5APFEN1 | |
| SCHEMBL14339664 | 0.91 | PRMT5 (0.42) | PRMT5TP53HTR6ALOX5APFEN1 | |
| SCHEMBL14028580 | 0.90 | PRMT5 (0.41) | PRMT5PARP1HTR6ALOX5APFEN1 | |
| SCHEMBL4946420 | 0.89 | PRMT5 (0.42) | PRMT5PARP1HTR6ALOX5APFEN1 | |
| SCHEMBL4940406 | 0.89 | PRMT5 (0.42) | PRMT5PARP1HTR6ALOX5APFEN1 | |
| SCHEMBL4947196 | 0.87 | PRMT5 (0.43) | PRMT5HTR6ALOX5APFEN1TLR9 | |
| SCHEMBL4945773 | 0.87 | PRMT5 (0.41) | PRMT5HTR6ALOX5APFEN1TLR9 | |
| SCHEMBL14028576 | 0.86 | PRMT5 (0.42) | PRMT5TP53HTR6ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435743-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-10-14 | — | — | US | disclosed |
| US-7435743-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-10-14 | — | — | US | disclosed |
| US-7435743-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-10-14 | — | — | US | disclosed |
| EP-1326856-B1 | PYRIDINE DERIVATIVES WITH IKB-KINASE (IKK-BETA) INHIBITING ACTIVITY | BAYER HEALTHCARE AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-7232909-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| US-7232909-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| US-7232909-B2 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2007-06-19 | — | — | US | disclosed |
| US-20060205676-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060100246-A1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | US | disclosed |
| US-6984649-B1 | Pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2006-01-10 | — | — | US | disclosed |
| CN-1476442-A | Pyridine derivatives with IKB-kinase (IKK-beta) INhibiting activity | — | 2004-02-18 | — | — | CN | disclosed |
| US-6562811-B1 | Inhibit I kappa B kinase beta (IKK- beta or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- kappa B) and can be used for the prophylaxis and treatment of inflammation | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205676-A1 | Pyridine derivatives | CBR3, ARG1, HRH3 | PRMT5 181/4885TP53 1603/4885PARP1 1747/4885 |
| US-20060100246-A1 | Pyridine derivatives | NAPRT, NNT, NANS | PRMT5 1544/4885TP53 3371/4885PARP1 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.